| Ytd | 79.54% | |
| 1y | 51.19% |
| Open | 55.10 | Prev Close | 54.94 | Low | 53.50 | High | 55.44 | Mkt Cap | 8.19B |
| Vol | 1.99M | Avg Vol | 2.33M | EPS | 2.86 | P/E | 18.71 | Forward P/E | 18.63 |
| Beta | 1.68 | Short Ratio | 15.25 | Inst. Own | 70.23% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-03 | 50-d Avg | 42.89 | 200-d Avg | 34.54 | 1yr Est | 51.71 |
TGTX News
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
TG Therapeutics shares are trading higher on Thursday as traders keep leaning into recent upbeat cli
3 health care stocks flashing warning: CAH RSI 77.7, TGTX RSI 79.8, AMRX RSI 76.9; all overbought, b
TG Therapeutics shares are trading higher on Wednesday as positive topline Phase 1 data fuels fresh
US stocks down, Dow Jones fell 150 pts on Wed. Caseys General Stores Inc (CASY) shares up 14.4% afte
TGTX stock rises on positive Phase 1 data for subcutaneous BRIUMVI in myasthenia gravis. See what
82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL obser
82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL obser
Shares of TG Therapeutics Inc (NASDAQ: TGTX) are climbing Wednesday after early-stage clinical trial
Dow falls 296 points. Navitas Semi rises on partnership with Nvidia. Other gainers: ABVX, MMED, KELY
Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen curre
TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the publication of data from a post-hoc pooled
HC Wainwright & Co. analyst Emily Bodnar reiterates TG Therapeutics (NASDAQ:TGTX) with a Buy
Phase 3 trial met its primary endpoint, demonstrating bioequivalent drug exposure between the curren
TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the upcoming schedule of presentations highligh
HC Wainwright & Co. analyst Emily Bodnar maintains TG Therapeutics (NASDAQ:TGTX) with a Buy a
TG Therapeutics (NASDAQ:TGTX) reported quarterly earnings of $0.18 per share which missed the analys
TG Therapeutics (NASDAQ:TGTX) raises FY2026 sales outlook from $875.000 million-$900.000 million to
BRIUMVI is currently approved in the United States and several ex-US territories as a one-hour intra
https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/october-december-2025-new-safety-
TG Therapeutics, Inc. ("TG" or "the Company"), (NASDAQ:TGTX), today announced that i
TG Therapeutics, Inc. ("TG" or "the Company"), (NASDAQ:TGTX), today announced that i
G Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of data from a post hoc pooled
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel
(Editor’s note: The future prices of benchmark tracking ETFs, and the headline were updated in the s
TCOM: -11% | Trip.com Group shares are trading lower after the company announce it is under investig
Retail investors are preparing for another busy week of earnings season with more than 1,600 compani
Top mid-cap stocks jumped up to 23.87%. Some reasons include strong gold/silver, better financial re
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings a
Shares of WD-40 Company (NASDAQ: WDFC) rose sharply during Wednesday’s session after the company rep
U.S. stocks traded slightly higher, with the Dow Jones index gaining over 20 points on Wednesday. S
Shares of Aehr Test Systems (NASDAQ: AEHR) shares fell sharply in pre-market trading after the comp